Neurocrine Biosciences, Inc. (BIT:1NBIX)

Market Cap	9.57B
Revenue (ttm)	2.27B
Net Income (ttm)	329.66M
Shares Out	n/a
EPS (ttm)	3.18
PE Ratio	29.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	94.70
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
RSI	n/a
Earnings Date	May 5, 2025

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,800
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1NBIX

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Financial numbers in USD